Graft-versus-host alloresponses to treat nonlymphohematopoietic tumors: is there a solid approach?

M Sykes¹

Affiliations

Comment

M Sykes. J Immunother. 2001 Mar-Apr.

. 2001 Mar-Apr;24(2):101-3.

M Sykes¹

No abstract available

Comment on

Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma.
Morecki S, Yacovlev E, Gelfand Y, Uzi I, Slavin S. Morecki S, et al. J Immunother. 2001 Mar-Apr;24(2):114-21. J Immunother. 2001. PMID: 11265768

Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
Ohashi M, Kobayashi A, Hara H, Miura Y, Yoshida K, Kushida M, Ikarashi Y, Mandai M, Kitajima M, Yoshida T, Aoki K. Ohashi M, et al. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2208-15. doi: 10.1158/1078-0432.CCR-05-2657. Clin Cancer Res. 2006. PMID: 16609036
Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation.
Pachnio A, Dietrich S, Klapper W, Humpe A, Schwake M, Sedlacek R, Gramatzki M, Beck C. Pachnio A, et al. Bone Marrow Transplant. 2006 Jul;38(2):157-67. doi: 10.1038/sj.bmt.1705411. Bone Marrow Transplant. 2006. PMID: 16820783
Haematopoietic cell transplantation as immunotherapy.
Appelbaum FR. Appelbaum FR. Nature. 2001 May 17;411(6835):385-9. doi: 10.1038/35077251. Nature. 2001. PMID: 11357147 Review.
Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma.
Morecki S, Yacovlev E, Gelfand Y, Uzi I, Slavin S. Morecki S, et al. J Immunother. 2001 Mar-Apr;24(2):114-21. J Immunother. 2001. PMID: 11265768
Exploiting beneficial alloreactive T cells.
Barber LD, Madrigal JA. Barber LD, et al. Vox Sang. 2006 Jul;91(1):20-7. doi: 10.1111/j.1423-0410.2006.00775.x. Vox Sang. 2006. PMID: 16756597 Review.